NO975127D0 - Anvendelse av ikke-steroidale antiinflammatoriske midler for å forbedre den fysiologiske forlikelighet av partikulære farmasöytiske preparater - Google Patents

Anvendelse av ikke-steroidale antiinflammatoriske midler for å forbedre den fysiologiske forlikelighet av partikulære farmasöytiske preparater

Info

Publication number
NO975127D0
NO975127D0 NO975127A NO975127A NO975127D0 NO 975127 D0 NO975127 D0 NO 975127D0 NO 975127 A NO975127 A NO 975127A NO 975127 A NO975127 A NO 975127A NO 975127 D0 NO975127 D0 NO 975127D0
Authority
NO
Norway
Prior art keywords
improve
pharmaceutical preparations
inflammatory agents
steroidal anti
physiological compatibility
Prior art date
Application number
NO975127A
Other languages
English (en)
Other versions
NO975127L (no
Inventor
Werner Krause
Peter Muschick
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7762219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO975127(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO975127D0 publication Critical patent/NO975127D0/no
Publication of NO975127L publication Critical patent/NO975127L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO975127A 1995-05-10 1997-11-07 Anvendelse av ikke-steroidale antiinflammatoriske midler for å forbedre den fysiologiske forlikelighet av partikulære farmasöytiske preparater NO975127L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19518221A DE19518221A1 (de) 1995-05-10 1995-05-10 Verwendung nichtsteroidaler Entzündungshemmer zur Verbesserung der physiologischen Verträglichkeit partikulärer pharmazeutischer Zubereitungen
PCT/EP1996/001936 WO1996035429A1 (de) 1995-05-10 1996-05-09 Verwendung nichtsteroidaler entzündungshemmer zur verbesserung der physiologischen verträglichkeit partikulärer pharmazeutischer zubereitungen

Publications (2)

Publication Number Publication Date
NO975127D0 true NO975127D0 (no) 1997-11-07
NO975127L NO975127L (no) 1997-12-10

Family

ID=7762219

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975127A NO975127L (no) 1995-05-10 1997-11-07 Anvendelse av ikke-steroidale antiinflammatoriske midler for å forbedre den fysiologiske forlikelighet av partikulære farmasöytiske preparater

Country Status (7)

Country Link
US (1) US5874422A (no)
EP (1) EP0831840A1 (no)
JP (1) JPH11504930A (no)
CA (1) CA2220052A1 (no)
DE (1) DE19518221A1 (no)
NO (1) NO975127L (no)
WO (1) WO1996035429A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
IL113926A (en) * 1995-05-31 2000-06-01 Korenstein Rafi Contrast medium with improved patient's tolerance thereto and its use
DE19721947C2 (de) * 1997-05-21 1999-04-22 Diagnostikforschung Inst Verwendung von pharmazeutischen Zubereitungen, die Partikel, Vesikel oder Polymere sowie nichtsteroidale Antirheumatika und/oder Thrombozytenaggregationshemmer zur Darstellung der Gefäße, Lymphknoten und des Knochenmarks enthalten
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
ES2173679T3 (es) 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
MXPA02000053A (es) * 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
WO2003077886A1 (fr) * 2002-03-20 2003-09-25 Hosokawa Micron Corporation Procede de fabrication de particules composites contenant un produit chimique
JP2006503840A (ja) * 2002-09-25 2006-02-02 フォーブス メディ−テック インコーポレーテッド ステロール及び／又はスタノール及び抗炎症剤の特定の種類を含有する新規構造体及び組成物、並びに、心血管疾患、その根底にある高脂血症を含む病気、及び原因又は症状の一部として炎症を有する他の障害の治療又は予防におけるそれらの使用
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20080095722A1 (en) * 2004-11-12 2008-04-24 Idea Ag Extended Surface Aggregates in the Treatment of Skin Conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH672733A5 (no) * 1987-05-22 1989-12-29 Bracco Ind Chimica Spa
US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents

Also Published As

Publication number Publication date
US5874422A (en) 1999-02-23
WO1996035429A1 (de) 1996-11-14
EP0831840A1 (de) 1998-04-01
DE19518221A1 (de) 1996-11-14
JPH11504930A (ja) 1999-05-11
NO975127L (no) 1997-12-10
CA2220052A1 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
ATE219377T1 (de) Neue galenische orale pharmazeutische formulierung
NO962490D0 (no) Orale formuleringer av S(+)-ibuprofen
NO994757D0 (no) FramgangsmÕte for oral administrasjon av proteiner
DE19681287T1 (de) Orale Formulierung von 2-Methylthienobenzodiazepin
NO973938L (no) Farmasöytisk preparat av piperidinoalkanolforbindelser
DE69328492D1 (de) Fettsäure-derivate und diese enthaltende pharmazeutische präparationen
NO180474C (no) Fremgangsmåte for potensiering av den analgetiske effekt av curcuminoider
NO953262D0 (no) Bedring av Dupuytrens sykdom
NO981388D0 (no) Bedring av Dupuytrens sykdom
NO995245L (no) Anvendelse av tetrahydropyridinderivater for fremstilling av medisiner for å behandle sykdommer som bevirker demyelinisering
KR970000228A (ko) S-에토돌락의 경구용 제제
NO953367D0 (no) Anvendelse av substituerte 4-fenyl-6-amino-nikotinsyre-derivater som legemidler
LV11666A (lv) Farmaceitiskie preparati un medikamenti endotelialo traucejumu noversanai un arstesanai
FR2754177B1 (fr) Microspheres pharmaceutiques d'acide valproique pour administration orale
NO975127D0 (no) Anvendelse av ikke-steroidale antiinflammatoriske midler for å forbedre den fysiologiske forlikelighet av partikulære farmasöytiske preparater
NO970198D0 (no) Anvendelse av glyceryltriacetat for behandling av onychomykoser
NO950134D0 (no) Formuleringer for oralt administrerte farmasöytiske midler
NO961797D0 (no) Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter
ATE256465T1 (de) Orale arzneimittel zubereitung von piperdinoalkanole in gelöster form
FR2744361B1 (fr) Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
NO950714L (no) Anvendelse av en tricyklisk forbindelse for fremstilling av medisinske preparater
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
NO951933D0 (no) Farmasöytiske formuleringer av ibuprofen
FR2744362B1 (fr) Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FI973277A0 (fi) Farmaseuttisia valmisteita TNF:n estämiseksi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application